History of myeloid-derived suppressor cells
Open accessThe DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Abstract
Tumour-induced granulocytic hyperplasia is associated with tumour vasculogenesis and escape from immunity via T cell suppression. Initially, these myeloid cells were identified as granulocytes or monocytes; however, recent studies have revealed that this hyperplasia is associated with populations of multipotent progenitor cells that have been identified as myeloid-derived suppressor cells (MDSCs). The study of MDSCs has provided a wealth of information regarding tumour pathobiology, has extended our understanding of neoplastic progression and has modified our approaches to immune adjuvant therapy. In this Timeline article, we discuss the history of MDSCs, their influence on tumour progression and metastasis, and the crosstalk between tumour cells, MDSCs and the host macroenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Myeloid-derived suppressor cells (MDSCs), a heterogeneous group of immune cells from the myeloid lineage, are a major component of the immunosuppressive TME [93].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [93]
The cited source says what the claim attributes to it.
In the citing paper
“The TME is immunosuppressive, thus rendering the immune system less effective in killing cancer cells.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Goycoolea, A. (1997) · Cited by 3,615
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S.-I., Kitamura, Y., Yoshida, N., Kikutani, H., & Kishimoto, T. (1996) · Nature · doi:10.1038/382635a0 · Cited by 2,338
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H., Inai, Y., Silver, M., & Isner, J. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.14.3964 · Cited by 1,856
Research works printed but not linked: 1
- Sonnenfeld A Leukamische reaktiones bei carcinoma Zeitschrift f Klin Med 1929 111
Cited by
Items 201–300 of 1,000
Romano, A., Parrinello, N. L., Vetro, C., Forte, S., Chiarenza, A., Figuera, A., Motta, G., Palumbo, G. A., Ippolito, M., Consoli, U., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13198 · Cited by 94
Icaritin promotes tumor T‐cell infiltration and induces antitumor immunity in mice
Hao, H., Zhang, Q., Zhu, H., Wen, Y., Qiu, D., Xiong, J., Fu, X., Wu, Y., Meng, K., & Li, J. (2019) · European Journal of Immunology · doi:10.1002/eji.201948225 · Cited by 102
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
Casadei, C., Dizman, N., Schepisi, G., Cursano, M. C., Basso, U., Santini, D., Pal, S. K., & Giorgi, U. D. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919890285 · Cited by 101
Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
De Veirman, K., Van Valckenborgh, E., Lahmar, Q., Geeraerts, X., De Bruyne, E., Menu, E., Van Riet, I., Vanderkerken, K., & Van Ginderachter, J. A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00349 · Cited by 95
Missiaen, R., Mazzone, M., & Bergers, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.002 · Cited by 94
Wu, M., Liu, X., Bai, H., Lai, L., Chen, Q., Huang, G., Liu, B., & Tang, G. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b00294 · Cited by 96
Kather, J. N., & Halama, N. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0441-6 · Cited by 100
Chen, J., Zheng, D.-X., Yu, X.-J., Sun, H.-W., Xu, Y.-T., Zhang, Y., & Xu, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1652540 · Cited by 98
Horikawa, N., Abiko, K., Matsumura, N., Baba, T., Hamanishi, J., Yamaguchi, K. D., Murakami, R., Taki, M., Ukita, M., Hosoe, Y., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0725-x · Cited by 96
Zhang, J., Fan, J., Zeng, X., Nie, M., Luan, J., Wang, Y., Ju, D., & Yin, K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.022 · Cited by 90
Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis
Neo, S., Tong, L., Chong, J., Liu, Y., Xu, J., Oliveira, M. M. S., Chen, Y., Chen, Z., Lee, K., Burduli, N., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi2952 · Cited by 98
Zhang, H.-B., Zhang, Y., Zhang, Y., Li, H., Ou, M., Yu, Y., Zhang, F., Yin, H., Mao, Z., & Mei, L. (2024) · Nature Communications · doi:10.1038/s41467-024-50769-0 · Cited by 99
The immunobiology of myeloid-derived suppressor cells in cancer
Motallebnezhad, M., Jadidi‐Niaragh, F., Qamsari, E. S., Bagheri, S., Gharibi, T., & Yousefi, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4477-9 · Cited by 97
Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis
Qin, G., Lian, J., Huang, L. J., Zhao, Q., Liu, S., Zhang, Z., Chen, X., Yue, D., Li, L., Li, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442167 · Cited by 97
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
Martino, E., Misso, G., Pastina, P., Costantini, S., Vanni, F., Gandolfo, C., Botta, C., Capone, F., Lombardi, A., Pirtoli, L., et al. (2016) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.25 · Cited by 94
Myeloid-Derived Suppressor Cells and Radiotherapy
Jiménez‐Cortegana, C., Galassi, C., Klapp, V., Gabrilovich, D. I., & Galluzzi, L. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1105 · Cited by 93
Self-citationWang, Z., Zhang, L., Wang, H., Xiong, S., Li, Y., Tao, Q., Xiao, W., Qin, H., Wang, Y., & Zhai, Z. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1646-4 · Cited by 97
Yin, T., Zhao, Z.-B., Guo, J., Wang, T., Yang, J.-B., Wang, C., Long, J., Ma, S., Huang, Q., Zhang, K., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3397 · Cited by 92
Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer
Mitri, D. D., & Alimonti, A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.005 · Cited by 100
Marini, O., Spina, C., Mimiola, E., Cassaro, A., Malerba, G., Todeschini, G., Perbellini, O., Scupoli, M. T., Carli, G., Facchinelli, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8507 · Cited by 94
Myeloid‐Derived Suppressor Cells and Therapeutic Strategies in Cancer
Katoh, H., & Watanabe, M. (2015) · Mediators of Inflammation · doi:10.1155/2015/159269 · Cited by 98
Generation of Myeloid Cells in Cancer: The Spleen Matters
Wu, C., Hua, Q., & Zheng, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01126 · Cited by 99
Role of chemokine pathways in hepatobiliary cancer
Ehling, J., & Tacke, F. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.017 · Cited by 94
The Hippo Pathway in Prostate Cancer
Salem, O., & Hansen, C. G. (2019) · Cells · doi:10.3390/cells8040370 · Cited by 102
Dickkopf-1: A Promising Target for Cancer Immunotherapy
Chu, H. Y., Chen, Z., Wang, L., Zhang, Z., Tan, X., Liu, S., Zhang, B., Lü, A., Yu, Y., & Zhang, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658097 · Cited by 94
Pernot, S., Évrard, S., & Khatib, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850856 · Cited by 98
Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer
Xiong, Y., Wang, Y., & Tiruthani, K. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2019.102034 · Cited by 89
Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment
Comen, E. A., Bowman, R. L., & Kleppe, M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00056 · Cited by 99
Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment
Gao, X., Sui, H., Zhao, S., Gao, X., Su, Y., & Qu, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585214 · Cited by 91
Regulation of Natural Killer Cell Function by STAT3
Cacalano, N. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00128 · Cited by 95
Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells
Di, S., Zhou, M., Pan, Z., Sun, R., Chen, M., Jiang, H., Shi, B., Luo, H., & Li, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00241 · Cited by 85
Intravasation as a Key Step in Cancer Metastasis
Zavyalova, M. V., Denisov, E. V., Таширева, Л. А., Savelieva, O. E., Кайгородова, Е. В., Krakhmal, N. V., & Михайлович, П. В. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919070071 · Cited by 99
Lin, Q., Ren, L., Jian, M., Xu, P., Li, J., Zheng, P., Feng, Q., Yang, L., Ji, M., Wei, Y., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1922-5 · Cited by 93
Liver Tropism in Cancer: The Hepatic Metastatic Niche
Mielgo, A., & Schmid, M. C. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037259 · Cited by 94
Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis
Zhou, S., & Chen, X. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86396 · Cited by 113
Radiotherapy and cGAS/STING signaling: Impact on MDSCs in the tumor microenvironment
Kho, V. M., Mekers, V. E., Span, P. N., Bussink, J., & Adema, G. J. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104298 · Cited by 93
Li, S., Wang, Q., Shen, Y., Hassan, M., Shen, J., Jiang, W., Su, Y., Chen, J., Bai, L., Zhou, W., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b03753 · Cited by 87
Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
Tumino, N., Pace, A. L. D., Besi, F., Quatrini, L., Vacca, P., & Moretta, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638841 · Cited by 90
Sarkar, O. S., Donninger, H., Rayyan, N. A., Chew, L. C., Stamp, B. F., Zhang, X., Whitt, A. G., Li, C., Hall, M. B., Mitchell, R. A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg3736 · Cited by 86
CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma
Yu, G., Bu, L., Zhao, Y., Mao, L., Deng, W., Wu, T., Zhang, W., & Sun, Z. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1151594 · Cited by 88
Barker, G., Leeuwenburgh, C., Brusko, T. M., Moldawer, L. L., Reddy, S. T., & Guirgis, F. W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081693 · Cited by 89
Pan, T. S., Liu, Y., Zhong, L. M., Shi, M. H., Duan, X. B., Wu, K., Yang, Q., Liu, C., Wei, J. Y., Ma, X. R., et al. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.1a1015-481rr · Cited by 84
Schafer, C. C., Wang, Y., Hough, K. P., Sawant, A., Grant, S. C., Thannickal, V. J., Zmijewski, J. W., Ponnazhagan, S., & Deshane, J. S. (2016) · Oncotarget · doi:10.18632/oncotarget.12249 · Cited by 86
Thompson, E. A., & Powell, J. D. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-023155 · Cited by 83
Shi, H., Han, X., Sun, Y., Shang, C., Wei, M., Ba, X., & Zeng, X. (2018) · Cancer Science · doi:10.1111/cas.13809 · Cited by 82
Won, W.-J., Deshane, J. S., Leavenworth, J. W., Oliva, C. R., & Griguer, C. E. (2019) · Cell Stress · doi:10.15698/cst2019.02.176 · Cited by 87
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Myeloid-derived suppressor cells (MDSCs), a heterogeneous group of immune cells from the myeloid lineage, are a major component of the immunosuppressive TME [93].”
Ortiz, M. L., Kumar, V., Martner, A., Mony, S., Donthireddy, L., Condamine, T., Seykora, J., Knight, S. C., Malietzis, G., Lee, G. H., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140835 · Cited by 80
Self-citationPenetrable Nanoplatform for “Cold” Tumor Immune Microenvironment Reeducation
Chen, Q., He, Y., Wang, Y., Li, C., Zhang, Y., Guo, Q., Zhang, Y., Chu, Y., Liu, P., Chen, H., et al. (2020) · Advanced Science · doi:10.1002/advs.202000411 · Cited by 83
Gómez‐Valenzuela, F., Escobar, E., Pérez‐Tomás, R., & Montecinos, V. P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.686792 · Cited by 88
Advances of cancer-associated fibroblasts in liver cancer
Peng, H., Zhu, E., & Zhang, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00406-z · Cited by 86
The temporal progression of lung immune remodeling during breast cancer metastasis
McGinnis, C. S., Miao, Z., Superville, D. A., Yao, W., Goga, A., Reticker-Flynn, N. E., Winkler, J., & Satpathy, A. T. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.004 · Cited by 82
Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment
Pan, X., & Zheng, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0505-9 · Cited by 75
Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer
Liu, D., You, M., Xu, Y., Li, F., Zhang, D., Li, X., & Hou, Y. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.07.035 · Cited by 80
García-Hernández, M. D. L. L., Uribe‐Uribe, N., Espinosa-González, R., Kast, W. M., Khader, S. A., & Rangel‐Moreno, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00563 · Cited by 83
The Emerging Understanding of Myeloid Cells as Partners and Targets in Tumor Rejection
Broz, M. L., & Krummel, M. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0041 · Cited by 74
Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients
Jordan, K. R., Kapoor, P., Spongberg, E., Tobin, R. P., Gao, D., Borges, V. F., & McCarter, M. D. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1953-z · Cited by 79
Heim, C. E., Vidlak, D., Odvody, J., Hartman, C. W., Garvin, K. L., & Kielian, T. (2017) · Journal of Orthopaedic Research® · doi:10.1002/jor.23806 · Cited by 79
Targeting the balance of T helper cell responses by curcumin in inflammatory and autoimmune states
Rahimi, K., Ahmadi, A., Hassanzadeh, K., Soleimani, Z., Sathyapalan, T., Mohammadi, A., & Sahebkar, A. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.05.012 · Cited by 81
Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives
Raimondo, S., Pucci, M., Alessandro, R., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072286 · Cited by 80
Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides
Vitale, I., Yamazaki, T., Wennerberg, E., Sveinbjørnsson, B., Rekdal, Ø., Demaria, S., & Galluzzi, L. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.12.012 · Cited by 84
Vendramin, A., Gimondi, S., Bermema, A., Longoni, P. D., Rizzitano, S., Corradini, P., & Carniti, C. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.09.011 · Cited by 78
Cancer immunotherapy in veterinary medicine: Current options and new developments
Regan, D. P., Guth, A., Coy, J. W., & DOW, S. W. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.10.008 · Cited by 93
The emerging role of myeloid-derived suppressor cells in lung diseases
Kolahian, S., Öz, H. H., Zhou, B., Griessinger, C. M., Rieber, N. P., & Hartl, D. (2016) · European Respiratory Journal · doi:10.1183/13993003.01572-2015 · Cited by 80
Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2
Rong, Y., Yuan, C., Qu, Z., Zhou, H., Guan, Q., Yang, N., Leng, X., Bu, L., Wu, K., & Wang, X. (2016) · Scientific Reports · doi:10.1038/srep23824 · Cited by 79
One microenvironment does not fit all: heterogeneity beyond cancer cells
Kim, I. S., & Zhang, X. H.-F. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9643-z · Cited by 79
Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.004 · Cited by 75
Fernandez, I. E., Greiffo, F. R., Frankenberger, M., Bandres, J., Heinzelmann, K., Neurohr, C., Hatz, R., Hartl, D., Behr, J., & Eickelberg, O. (2016) · European Respiratory Journal · doi:10.1183/13993003.01826-2015 · Cited by 75
Yu, G., Luo, M., Li, H., Chen, S., Huang, B., Sun, Z., Cui, R., & Zhang, M. (2019) · ACS Nano · doi:10.1021/acsnano.9b05038 · Cited by 76
The Engagement Between MDSCs and Metastases: Partners in Crime
Trovato, R., Canè, S., Petrova, V., Sartoris, S., Ugel, S., & Sanctis, F. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00165 · Cited by 79
Maenhout, S. K., Thielemans, K., & Aerts, J. L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.956579 · Cited by 74
Regulatory T-Cell Therapy in the Induction of Transplant Tolerance: The Issue of Subpopulations
Edozie, F. C., Nova‐Lamperti, E., Povoleri, G. A. M., Scottà, C., John, S., Lombardi, G., & Afzali, B. (2014) · Transplantation · doi:10.1097/tp.0000000000000243 · Cited by 82
Zöller, M., Zhao, K., Kutlu, N. N., Bauer, N., Provazník, J., Hackert, T., & Schnölzer, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01279 · Cited by 76
Liu, Q., Liao, Q., & Zhao, Y. (2015) · Medical Hypotheses · doi:10.1016/j.mehy.2015.12.007 · Cited by 74
Younis, R., Han, K., & Webb, T. (2016) · Journal of Immunology · doi:10.4049/jimmunol.1501293 · Cited by 67
Cancer-Associated Myeloid Regulatory Cells
Vlaeminck, Y. D., González-Rascón, A. A., Goyvaerts, C., & Breckpot, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00113 · Cited by 81
Tomita, Y., Lee, M.-J., Lee, S., Tomita, S., Chumsri, S., Cruickshank, S., Ordentlich, P., & Trepel, J. B. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1219008 · Cited by 72
Gao, Y., Wang, T., Li, Y., Zhang, Y., & Yang, R. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701721 · Cited by 77
Botta, C., Gullà, A., Correale, P., Tagliaferri, P., & Tassone, P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00348 · Cited by 76
Yang, X., Huang, C., Zhong, M., Zhong, H., Ruan, R., Xiong, J., Yao, Y., Zhou, J., & Deng, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02033-1 · Cited by 75
High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy
Kalathil, S. G., & Thanavala, Y. M. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1810-0 · Cited by 74
Lnc-C/EBPβ Negatively Regulates the Suppressive Function of Myeloid-Derived Suppressor Cells
Gao, Y., Sun, W., Shang, W., Li, Y., Zhang, D., Wang, T., Zhang, X., Zhang, S., Zhang, Y., & Yang, R. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0108 · Cited by 75
Song, M., Liang, J., Wang, L., Li, W., Jiang, S., Xu, S., Tang, L., Du, Q., Liu, G., Meng, H., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110757 · Cited by 74
Immune modulatory therapies for spinal cord injury – Past, present and future
Plemel, J. R., Yong, V. W., & Stirling, D. P. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.01.025 · Cited by 78
Emerging therapeutic targets in metastatic progression: A focus on breast cancer
Li, Z., & Kang, Y. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.003 · Cited by 75
Gao, X., Tian, L., Wu, J., Ma, X., Zhang, C., Zhou, Y., Sun, Y., Hu, B., Qiu, S., Zhou, J., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12831 · Cited by 73
Targeting complement-mediated immunoregulation for cancer immunotherapy
Kolev, M. V., & Markiewski, M. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.003 · Cited by 72
Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer
He, Z., Zhang, C., Zhao, Y., He, S., Li, Y., Shi, B., Hu, J., Qi, R., & Hua, B. (2023) · Discover Oncology · doi:10.1007/s12672-023-00793-1 · Cited by 76
Aghapour, S. A., Torabizadeh, M., Bahreiny, S. S., Saki, N., Far, M. A. J., Avarvand, A. Y., Ghasemi, K. D. M., Aghaei, M., Abolhasani, M. M., Sharifani, M. S., et al. (2024) · Iranian Journal of Blood and Cancer · doi:10.61186/ijbc.16.2.84 · Cited by 72
Lim, H. X., Hong, H.-J., Cho, D., & Kim, T. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401282 · Cited by 67
Sayed, M. F. A., Amrein, M. A., Bührer, E. D., Huguenin, A.-L., Radpour, R., Riether, C., & Ochsenbein, A. F. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3026 · Cited by 74
The CXCL12 Crossroads in Cancer Stem Cells and Their Niche
López-Gil, J. C., Martín-Hijano, L., Hermann, P. C., & Sáinz, B. (2021) · Cancers · doi:10.3390/cancers13030469 · Cited by 70
Liu, M., Zhou, J., Chen, Z., & Cheng, A. S. L. (2016) · The Journal of Pathology · doi:10.1002/path.4832 · Cited by 72
Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis
Mazzone, M., & Bergers, G. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114721 · Cited by 74
Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD
Koehn, B. H., Saha, A., McDonald-Hyman, C. S., Loschi, M. L., Thangavelu, G., Ma, L., Zaiken, M. C., Dysthe, J., Krepps, W., Panthera, J., et al. (2019) · Blood · doi:10.1182/blood.2019001950 · Cited by 70
Okuma, A., Hanyu, A., Watanabe, S., & Hara, E. (2017) · Nature Communications · doi:10.1038/s41467-017-02281-x · Cited by 69
The role of the innate immune system in the development and treatment of hepatocellular carcinoma
Roderburg, C., Wree, A., Demir, M., Schmelzle, M., & Tacke, F. (2020) · Hepatic Oncology · doi:10.2217/hep-2019-0007 · Cited by 69
Zhao, T., Du, H., Ding, X., Walls, K., & Yan, C. (2014) · Oncogene · doi:10.1038/onc.2014.143 · Cited by 69
Twardowski, P. W., Kanaya, N., Frankel, P. H., Synold, T. W., Ruel, C., Pal, S. K., Junqueira, M., Prajapati, M., Moore, T., Tryon, P., et al. (2015) · Cancer · doi:10.1002/cncr.29421 · Cited by 69
Li, D., Qi, J., Wang, J., Pan, Y., Li, J., Xia, X., Dou, H., & Hou, Y. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.08.013 · Cited by 73
Metadata
- Authors
- Talmadge, J. E., & Gabrilovich, D. I.
- Affiliations
- University of Nebraska Medical Center (US)
- The Wistar Institute (US)
- Corresponding author
- Talmadge, James E.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 739-752
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC4358792
- OpenAlex
- W2122403898
- Cited by
- 1,148
- References
- 197
- Citations by year
- 2026: 29 · 2025: 57 · 2024: 80 · 2023: 74 · 2022: 105 · 2021: 132 · 2020: 110 · 2019: 95 · 2018: 101 · 2017: 90 · 2016: 129 · 2015: 93 · 2014: 43 · 2013: 7
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA084488, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, tumor microenvironment, T cell suppression, immune evasion, tumor progression, metastasis, multipotent progenitors
- MeSH terms
- Animals, Antigens, Differentiation, Antigens, Neoplasm, Cell Differentiation, Cell Biology, Hematopoiesis, Extramedullary, Humans, Leukemoid Reaction, Medical Oncology, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Chemokines, Cell Lineage, Tumor Escape, Hematopoietic Stem Cell Mobilization, Myeloid Cells, Myeloid Progenitor Cells, Multipotent Stem Cells, Tumor Burden, History, 20th Century, History, 21st Century, Mice, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.